(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announce that it presented topline data from its phase I/II dose escalation study of immunoconjugate LDOS47 as a monotherapy in non-squamous non-small cell lung cancer patients at the 17th IASCLC World Conference on Lung Cancer (“WCLC”) held in Vienna, Austria.
- 0 Comments
- FY2017